Faldaprevir: all 40 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or TacrolimusCompletedNCT02016625Phase 1Results posted
• Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.CompletedNCT01965431Phase 1Results posted
• Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired PatientsTerminatedNCT01957657Phase 1Results posted
• Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and LevonorgestrelTerminatedNCT01941615Phase 1Results posted
• Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver CirrhosisCompletedNCT01909778Phase 1Results posted
• Pharmacokinetics of Faldaprevir of Soft CapsuleCompletedNCT01821937Phase 1Results posted
• Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and RosuvastatinCompletedNCT01795937Phase 1Results posted
• Investigation of Faldaprevir Effect on Pharmacokinetics of RaltegravirCompletedNCT01785160Phase 1Results posted
• Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral SolutionsCompletedNCT01764945Phase 1Results posted
• Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female SubjectsCompletedNCT01737996Phase 1Results posted
• IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1CompletedNCT01732796Phase 3Results posted
• Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2CompletedNCT01728324Phase 3Results posted
• Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine CapsulesCompletedNCT01704846Phase 1Results posted
• Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/NaloxoneCompletedNCT01637922Phase 1Results posted
• Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal ImpairmentCompletedNCT01580306Phase 1Results posted
• Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination TrialCompletedNCT01579474Phase 3Results posted
• Drug-drug Interaction of BI 201335 and MicrogynonCompletedNCT01570244Phase 1Results posted
• This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis CCompletedNCT01528735Phase 2Results posted
• Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCompletedNCT01525628Phase 1Results posted
• Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)CompletedNCT01399619Phase 3Results posted
• Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female VolunteersCompletedNCT01374802Phase 1Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)CompletedNCT01358864Phase 3Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)CompletedNCT01343888Phase 3Results posted
• Drug Drug Interaction of BI 201335 and TenofovirCompletedNCT01340196Phase 1Results posted
• A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected PatientsCompletedNCT01330316Phase 3Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)CompletedNCT01297270Phase 3Results posted
• Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 InfectionCompletedNCT01132313Phase 2Results posted
• Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)CompletedNCT00984620Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) PatientsCompletedNCT00947349Phase 2Results posted
• Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -ExperiencedCompletedNCT00793793Phase 1Results posted
• A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus InfectionCompletedNCT02593162Phase 2
• Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male VolunteersTerminatedNCT02182401Phase 1
• Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male SubjectsCompletedNCT02182362Phase 1
• Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male VolunteersCompletedNCT02182349Phase 1
• Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy VolunteersCompletedNCT02182336Phase 1
• Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male SubjectsCompletedNCT02182323Phase 1
• Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male SubjectsCompletedNCT02182310Phase 1
• Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male SubjectsCompletedNCT02182297Phase 1
• Single Rising Dose Study of BI 201335 ZW in Healthy Male SubjectsTerminatedNCT02182271Phase 1
• A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C InfectionWithdrawnNCT01608737Phase 3

← Faldaprevir overview